IL162699A0 - Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2- selective inhibitors - Google Patents

Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2- selective inhibitors

Info

Publication number
IL162699A0
IL162699A0 IL16269903A IL16269903A IL162699A0 IL 162699 A0 IL162699 A0 IL 162699A0 IL 16269903 A IL16269903 A IL 16269903A IL 16269903 A IL16269903 A IL 16269903A IL 162699 A0 IL162699 A0 IL 162699A0
Authority
IL
Israel
Prior art keywords
cyclooxygenase
combinations
activated receptor
selective inhibitors
peroxisome proliferator
Prior art date
Application number
IL16269903A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL162699A0 publication Critical patent/IL162699A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IL16269903A 2002-01-14 2003-01-14 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2- selective inhibitors IL162699A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34829702P 2002-01-14 2002-01-14
US10/341,217 US20030212138A1 (en) 2002-01-14 2003-01-13 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
PCT/US2003/000956 WO2003059294A2 (en) 2002-01-14 2003-01-14 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor

Publications (1)

Publication Number Publication Date
IL162699A0 true IL162699A0 (en) 2005-11-20

Family

ID=26992419

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16269903A IL162699A0 (en) 2002-01-14 2003-01-14 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2- selective inhibitors

Country Status (10)

Country Link
US (1) US20030212138A1 (xx)
EP (1) EP1569640A4 (xx)
JP (1) JP2005525313A (xx)
KR (1) KR20040095207A (xx)
AU (1) AU2003207535A1 (xx)
CA (1) CA2472168A1 (xx)
IL (1) IL162699A0 (xx)
MX (1) MXPA04006796A (xx)
PL (1) PL374962A1 (xx)
WO (1) WO2003059294A2 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152752A1 (en) * 2002-05-30 2004-08-05 Chong Kong Teck Treatment for human papillomavirus
EP2295529B2 (en) 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
SE0202188D0 (sv) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
AU2003300264A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
US7601756B2 (en) 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
CA2534816A1 (en) * 2003-06-12 2004-12-23 Evan Newell Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
WO2005115370A2 (en) * 2004-04-23 2005-12-08 The Regents Of The University Of California Compounds and methods for treating non-inflammatory pain using pparalpha agonists
DE102004022253A1 (de) * 2004-05-04 2005-12-08 Phenion Gmbh & Co. Kg Verwendung von Pirinixinsäure und deren Salzen zur Behandlung von chronisch entzündlichen Krankheiten
JP2005350451A (ja) * 2004-05-11 2005-12-22 Santen Pharmaceut Co Ltd 角結膜障害治療剤
CA2571683A1 (en) * 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
ITMI20041825A1 (it) * 2004-09-24 2004-12-24 Medestea Res & Production Srl Agonisti dei ricettori attivanti la proliferazione dei perossisomi, utili nella prevenzione o nel trattamento della gastrite
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
WO2006116217A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
WO2006118821A2 (en) * 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
WO2007106912A2 (en) * 2006-03-16 2007-09-20 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peroxisome-proliferator activated receptor-alpha agonists for organ preservation
US20100015085A1 (en) * 2006-05-01 2010-01-21 Johns Hopkins University Phase 2 inducers and related signaling pathways protect cartilage against inflammation/infection, apoptosis and stress
FR2999936B1 (fr) * 2012-12-21 2015-01-16 Urgo Lab Utilisation d'acide acetylsalicylique pour la prevention et/ou le traitement des plaies du diabetique
CN105636935B (zh) * 2013-10-01 2018-04-03 欧拉泰克治疗有限责任公司 3‑苄磺酰基丙腈的药学用途
US9999610B2 (en) 2013-10-01 2018-06-19 Olatec Therapeutics Llc Pharmaceutical use of 3-benzylsulfonylpropionitrile
KR101724585B1 (ko) * 2014-09-15 2017-04-10 경북대학교 산학협력단 Pdk 억제제를 유효성분으로 함유하는 만성 염증성 통증 치료용 조성물
CA2989052C (en) 2015-06-15 2020-11-24 Rush Unversity Medical Center Brain derived ppar.alpha. ligands
EP3468604B1 (en) * 2016-06-08 2021-01-20 Support-Venture GmbH Pharmaceutical combinations for treating cancer
KR101826697B1 (ko) * 2016-08-25 2018-02-07 경북대학교 산학협력단 Pdk 억제제를 유효성분으로 함유하는 만성 염증성 통증 치료용 조성물
CN115417825A (zh) * 2022-08-15 2022-12-02 山东大学 一种五元或六元稠环并嘧啶类环丙基萘衍生物及其制备方法与应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
TW245716B (xx) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
DK0731795T3 (da) * 1993-11-30 2000-05-15 Searle & Co Substituerede pyrazolylbenzensulfonamider til behandling af inflammation
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
RU2200158C2 (ru) * 1995-02-13 2003-03-10 Джи.Ди.Сирл энд Ко. Замещенные изоксазолы, фармацевтические композиции на их основе и способ подавления воспалений
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
ES2150679T3 (es) * 1995-07-21 2000-12-01 Nycomed Austria Gmbh Derivados de bencenosulfonamidas como inhibidores de la enzima ciclooxigenasa ii.
JP4422796B2 (ja) * 1995-07-21 2010-02-24 タクティカル セラピューティクス インコーポレイテッド アミノイミダゾールカルボキサミドおよび５−アミノ、または置換アミノ１，２，３−トリアゾールの塩による癌の治療および阻止
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
EP0788353A1 (en) * 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) * 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6222048B1 (en) * 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
CN1098256C (zh) * 1996-04-12 2003-01-08 G·D·瑟尔公司 作为cox－2抑制剂前药的取代的苯磺酰胺衍生物
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
TR199802538T2 (xx) * 1996-06-07 2001-01-22 The Procter & Gamble Company �ltihaplanmaya kar�� maddeler olarak yararl� dihidrobenzopiran ve ili�kili bile�ikler.
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
ATA16597A (de) * 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
DE69810938T2 (de) * 1997-04-11 2003-11-06 Grelan Pharmaceutical Co Pyrazolderivate und sie enthaltende cox-inhibitoren
US6130334A (en) * 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6127545A (en) * 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
WO1999003837A1 (en) * 1997-06-30 1999-01-28 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
AP9801302A0 (en) * 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US5925769A (en) * 1997-09-09 1999-07-20 Ortho Pharmaceutical, Corp. Acetylenic 1,5-diarylpyrazoles as antiinflammatory agents
US6046217A (en) * 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6140515A (en) * 1997-09-24 2000-10-31 Merck & Co., Inc. Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of COX-2
US6040450A (en) * 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6080876A (en) * 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
US6133292A (en) * 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
ES2259459T3 (es) * 1997-11-19 2006-10-01 Takeda Pharmaceutical Company Limited Nuevos inhibidores de apoptosis.
US6242196B1 (en) * 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
JP3256513B2 (ja) * 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US5994379A (en) * 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
KR100295206B1 (ko) * 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6153432A (en) * 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
JP2003501464A (ja) * 1999-06-16 2003-01-14 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション シクロオキシゲナーゼ−２の阻害剤としての１−（４−スルファミルアリール）−３−置換−５−アリール−２−ピラゾリン
MXPA00006605A (es) * 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
US6077868A (en) * 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6306890B1 (en) * 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
US6359182B1 (en) * 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof

Also Published As

Publication number Publication date
MXPA04006796A (es) 2004-12-06
KR20040095207A (ko) 2004-11-12
AU2003207535A2 (en) 2003-07-30
EP1569640A2 (en) 2005-09-07
WO2003059294A2 (en) 2003-07-24
CA2472168A1 (en) 2003-07-24
JP2005525313A (ja) 2005-08-25
WO2003059294A3 (en) 2005-07-14
EP1569640A4 (en) 2006-06-21
AU2003207535A1 (en) 2003-07-30
US20030212138A1 (en) 2003-11-13
PL374962A1 (en) 2005-11-14

Similar Documents

Publication Publication Date Title
IL162699A0 (en) Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2- selective inhibitors
IL162698A0 (en) Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxyge
AU2003303128A8 (en) Inhibitors and methods of use thereof
IL165280A (en) 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2b and alpha-2c adrenergic receptors
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
AU2003259735A8 (en) Small-mer compositions and methods of use
EP1538907A4 (en) FTSZ-HEMMER AND ITS USE
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
EP1465615A4 (en) TRICYCLIC BISENONE DERIVATIVES AND METHODS OF USE
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
EP1448218A4 (en) BETA SECRETASE INHIBITORS AND METHODS OF USE
EP1423081A4 (en) COMPOSITION COMPRISING GLYCOSAMINOGLYCANS AND HYALURONIDASE INHIBITORS FOR THE TREATMENT OF ARTHRITIC ARTICULATIONS
IL161992A0 (en) Substituted 2-amino-cycloalkanecarboxamides and t heir use as cysteine protease inhibitors
NO20043907L (no) Partielle og fullstendige agonister av A1-adenosinreseptorer
AU2003299441A8 (en) Nf-hev compositions and methods of use
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
EP1476150A4 (en) CARBOXY FULLERES AND USE METHOD THEREFOR
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
EP1385872A4 (en) NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS
AU2003278157A1 (en) Novel phenylethanolamine derivatives and the use of the same as beta-3-agonists
AU2003278814A8 (en) Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
AU2002347985A1 (en) Peroxisome proliferator activated receptor alpha agonists
AU2003285686A8 (en) Glycoisoforms of adiponectin and uses thereof
AU2003282593A8 (en) Polyphenolamine composition and method of use